(EMAILWIRE.COM, December 27, 2017 ) The Asia Pacific Diabetic Retinopathy Market has been estimated at USD 1.46 billion in 2016 and is projected to reach USD 2.15 billion by 2021, at a CAGR of 7.94% during the forecast period from 2016 to 2021.

Asia is predicted to show the wealthy growth in the forecast period. Within the Asian region, western pacific region account for larger share of blindness due to DR when equated to South-East Asia. The major factor contributing to the increasing share of Diabetic Retinopathy among the growing economies are huge pool of patients and increasing support and funding given by the government.

Full report at: http://www.marketdataforecast.com/market-reports/asia-pacific-diabetic-retinopathy-market-939/

Diabetic retinopathy is considered as a severe sight threatening problem that results due to chronic diabetes. The treatment for diabetic retinopathy may require intraocular injections, anti VEGF drugs, laser surgery or vitrectomy depending on the severity of the condition.

Rapidly expanding diabetic population coupled with increasing awareness of people regarding diabetic retinopathy is expected to drive the growth of global diabetic retinopathy drug market in coming years. Rising medical procedures due to high penetration of medical insurance and rising government initiatives for prevention of diabetes related risks is also believed to garner the growth of retinopathy drug market in future.

The Asia Pacific Diabetic Retinopathy Market has been segmented on the basis of indication into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). NPDR is further sub segmented as Mild, Moderate and Severe. Based on Treatment type the market is bifurcated into Anti-Vascular Endothelial Growth Factor (VEGF) drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy.

By end users division is among Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers. Non-proliferative retinopathy dominated the overall market size estimated to lead the market. Augmented occurrence of diabetes, lack of diagnosis at right time, and non-compliant retinal screening of diabetic patients are predictable to drive the growth of non-proliferative diabetic retinopathy market share. In addition, based on geography the Asia Pacific Diabetic Retinopathy Market is analysed under the regions of India. China, Japan, Australia and South Korea.

Request sample: https://www.marketdataforecast.com/cart/buy-now/asia-pacific-diabetic-retinopathy-market-939

The Major companies in Diabetic Retinopathy treatment market are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd, Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.

About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com

Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases

Contact Information:
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results